Overprescribing of lipid lowering agents

Quality and Safety in Health Care

Volumn 15, Issue 4, 2006, Pages 251-257

  Smith, M A ^a   Cox, E D ^a   Bartell, J M ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Group Health Cooperative of South Central WI Administrative Offices   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL DIET; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HUMAN EXPERIMENT; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL PRACTICE; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET, FAT-RESTRICTED; DRUG PRESCRIPTIONS; DRUG UTILIZATION REVIEW; EDUCATION, MEDICAL; HEALTH CARE SURVEYS; HEALTH SERVICES MISUSE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MEDICINE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; PRIVATE PRACTICE; QUESTIONNAIRES; REGRESSION ANALYSIS; SPECIALIZATION; SPECIALTIES, MEDICAL; UNITED STATES;

EID: 33747249552     PISSN: 14753898     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.2005.016162     Document Type: Article

References (40)

1. Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am J Cardiol 1998;82:61-5.
2. Jacobson TA, Schein JR, Williamson A, et al. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med 1998;158:1977-89.
3. National Cholesterol Education Program. Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), Publication No 02-5215. Bethesda, MD: National Institutes of Health, 2002.
4. Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002;105:152-6.
5. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
6. IMS Health. Leading 20 therapeutic classes by US sales, Available at http://www.imshealth.com/ims/portal/front/articleC/0,2777, 6599_49695983_54699443,00.html (accessed 3 September 2004).
7. Meyer BM, Cantwell KM. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003: implications for health-system pharmacy. Am J Health Syst Pharm 2004;61:1042-51.
8. Layne RD, Sehbai AS, Stark LJ. Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 2004;38:232-4.
9. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107.
10. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90.
11. Dubois RW, Alexander CM, Wade S, et al. Growth in use of lipid-lowering therapies: are we targeting the right patients? Am J Manag Care 2002;8:862-7.
12. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care 2001;39:S46-54.
13. Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001;39:S2-45.
14. Zachry WM, Shepherd MD, Hinich MJ, et al. Relationship between direct-to-consumer advertising and physician diagnosing and prescribing. Am J Health Syst Pharm 2002;59:42-9.
15. Watkins C, Harvey I, Carthy P, et al. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care 2003;12:29-34.
16. Kemper P, Blumenthal D, Corrigan JM, et al. The design of the Community Tracking Study: a longitudinal study of health system change and its effects on people. Inquiry 1996;33:195-206.
17. Keil L, Chattopadhyay M, Potter F, et al. Community Tracking Study Physician Survey: Survey Methodology Report (Round 1, Release 1), Report No 9, Technical Publication. Washington, DC: Center for Studying Health System Change, 1998.
18. National Cholesterol Education Program Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-23.
19. Flynn KE, Smith MA, Davis MK. From physician to consumer: the effectiveness of strategies to manage health care utilization. Med Care Res Rev 2002;59:455-81.
20. Anon. Community Tracking Study Physician Survey Public Use File: User's Guide, Round 2, Release 1, Report No 25. Washington, DC: Center for Studying Health System Change, 2001.
21. Reschovsky J, Reed M, Blumenthal D, et al. Physicians' assessments of their ability to provide high-quality care in a changing health care system. Med Care 2001;39:254-69.
22. Maldonodo G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36.
23. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care 2002;8:1041-54.
24. Tunis SR, Hayward RS, Wilson MC, et al. Internists' attitudes about clinical practice guidelines. Ann Intern Med 1994;120:956-63.
25. Troein M, Rastam L, Selander S. Dissemination and implementation of guidelines for lipid lowering. Fam Pract 1991;8:223-8.
26. Underwood P, Beck P. Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues. Qual Saf Health Care 2002;11:230-2.
27. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care: a critical analysis of the experimental literature. Milbank Q 1989;67:268-317.
28. Soumerai SB, Avorn J. Predictors of physician prescribing change in an educational experiment to improve medication use. Med Care 1987;25:210-21.
29. Unwin N, Thomson R, O'Byrne AM, et al. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ 1998;317:1125-30.
30. Dhalla IA, Anderson GM, Mamdani MM, et al. Inappropriate prescribing before and after nursing home admission. J Am Geriatr Soc 2002;50:995-1000.
31. Anderson GM, Beers MH, Kerluke K. Auditing prescription practice using explicit criteria and computerized drug benefit claims data. J Eval Clin Pract 1997;3:283-94.
32. Ray WA, Federspiel CF, Schaffner W. Prescribing of chloramphenicol in ambulatory practice. An epidemiologic study among Tennessee Medicaid recipients. Ann Intern Med 1976;84:266-70.
33. Peabody JW, Luck J, Glassman P, et al. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA 2000;283:1715-22.
34. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
35. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
36. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80.
37. Villanueva P, Peiro S, Librero J, et al. Accuracy of pharmaceutical advertisements in medical journals. Lancet 2003;361:27-32.
38. Grundy SM, Balady GJ, Criqui MH, et al. Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee. Circulation 1997;95:2329-31.
39. NCQA National Committee for Quality Assurance. Annual Member Health Care Survey Manual, Version 1.0. Washington, DC: National Committee for Quality Assurance, 1995.
40. NCQA National Committee for Quality Assurance. Health Plan Employer Data and Information Set (HEDIS) 3.0. Washington, DC: National Committee for Quality Assurance, 1997.